Back to News
Market Impact: 0.3
Aptevo Therapeutics Inc. Reports 21% of Frontline AML Patients in Mipletamig Combination Study Advanced to Stem Cell Transplant
Source: Nasdaq
Healthcare & BiotechCompany Fundamentals
Aptevo Therapeutics reported that 10 of 47 evaluable patients (21%) with newly diagnosed acute myeloid leukemia advanced to allogeneic stem cell transplant after receiving mipletamig with venetoclax and azacitidine. The excerpt provides no comparator, additional efficacy or safety results, or market reaction.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.25
Ticker Sentiment
APVO0.65
More News
- From Wall Street to Silicon Valley, Anthropic IPO poised to have massive 'trickle-down effect'
- Microsoft offers buyouts to nearly 30% of workforce in ongoing AI shift
- Anthropic’s risk factors include the end of humanity, a feud with the Pentagon, and CEO Dario Amodei’s reputation
- Elon Musk warns more than 200 AI cloud companies face ‘guppy-level death’ as the AI boom runs into a debt crisis
- Why is PagSeguro Digital stock plummeting 30% today?
- Anthropic’s IPO filing shows explosive growth, risks and staggering costs